News from myos rens technology A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 07, 2019, 17:14 ET MYOS RENS Technology Reports Third Quarter 2019 Financial Results Including Year-Over-Year Revenue Growth of 430%

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, an innovative...


Nov 05, 2019, 07:00 ET MYOS RENS Technology Launches Exclusive 'Veterinarian Strength' Myos Canine Muscle Formula

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, the unique...


Oct 31, 2019, 06:00 ET MYOS RENS Technology Announces the Date for the Release of Third Quarter 2019 Financial Results, Conference Call and Webcast

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary...


Sep 10, 2019, 08:00 ET MYOS RENS Technology Enters into Research Agreement with McMaster University to Study Impact of Fortetropin® on Muscle Disuse Atrophy in Young Men

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary...


Jul 31, 2019, 13:08 ET MYOS RENS Technology Announces the Date for the Release of Second Quarter and First Half 2019 Results, Conference Call and Webcast

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary...


Mar 28, 2019, 06:00 ET MYOS RENS Technology Reports Fourth Quarter and Fiscal 2018 Results

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary...


Mar 26, 2019, 07:30 ET MYOS RENS Technology Announces the Date for the Release of Fourth Quarter and Fiscal Year 2018 Results, Conference Call and Webcast

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary...


Feb 27, 2019, 07:16 ET MYOS RENS Technology Announces Initiation of a Study at Kansas State University to Evaluate the Impact of Fortetropin® on Quality of Life and Activity in Geriatric Dogs

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary...


Jan 23, 2019, 08:00 ET MYOS CEO Joseph Mannello Issues Letter to Shareholders Following Presentation at North American Veterinary Community (NAVC) Conference/VMX

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary...


Jan 15, 2019, 07:00 ET MYOS RENS Technology Announces Study Results Demonstrating Fortetropin®, the Active Ingredient in Myos Canine Muscle Formula, Prevents Muscle Loss in Canines After Surgery and Enhances Recovery

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a...


Jan 08, 2019, 06:05 ET MYOS RENS Technology Announces Upcoming Presentation of Results from a Kansas State University Study Evaluating the Impact of Fortetropin® on Canine Muscle Loss after Surgery, at a Major Veterinary Conference, January 20, 2019

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a...


Jan 03, 2019, 06:05 ET MYOS RENS Technology Receives a New Patent from the United States Patent and Trademark Office

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a...


Dec 13, 2018, 16:06 ET MYOS RENS Technology Announces Results of Its 2018 Annual Meeting of Stockholders

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a...


Dec 11, 2018, 06:05 ET MYOS RENS Technology Launches 'Yolked®', Its Sports Nutrition Product, With The Vitamin Shoppe® Nationwide

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a...


Dec 06, 2018, 06:10 ET MYOS RENS Technology Announces Approval of $1.2 Million in NJEDA NOL Program Tax Credits

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a...


Nov 08, 2018, 06:10 ET MYOS RENS Technology Signs Distribution Agreement With Miller Veterinary Supply East To Bring Innovative MYOS Canine Muscle Formula™ To 6,000+ Veterinary Hospitals

MYOS RENS Technology Inc. ("MYOS" or "the Company") (Nasdaq: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a...


Nov 06, 2018, 17:26 ET MYOS RENS Technology Announces The Date For The Release Of Third Quarter 2018 Results, Conference Call And Webcast

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ:MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a...


Oct 02, 2018, 06:10 ET Centers For Medicare and Medicaid Services Approves Reimbursement For Unique Fortetropin®-Based Enteral Nutrition Formula

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a...


Aug 02, 2018, 06:15 ET MYOS RENS Technology Announces The Date For The Release Of Second Quarter And First Half 2018 Results, Conference Call And Webcast

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a...


Mar 28, 2018, 01:53 ET MYOS RENS Technology CEO Joseph Mannello Provides Comments On Operational And Financial Results For Fiscal Year 2017

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin®, a proprietary ingredient that...


Mar 20, 2018, 04:19 ET MYOS RENS Technology Announces the Date for the Release of Fourth Quarter and Year Ended December 31, 2017 Results, Conference Call and Webcast

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin®, the natural food product that...


Feb 15, 2018, 06:05 ET MYOS RENS Technology to Showcase Fortetropin® and the Qurr® Line of Muscle Health Products at the 2018 Arnold Sports Festival in Columbus, OH from March 2-4, 2018

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin®, the fertilized egg yolk-based...


Jan 16, 2018, 06:05 ET MYOS RENS Technology Launches 30-Day Qurr® Fortetropin® Challenge

MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin®, the natural food product that...


Jan 11, 2018, 06:05 ET MYOS RENS Technology CEO Issues Shareholder Letter

Today, the CEO of MYOS RENS Technology Inc. ("MYOS" or "the Company") (Nasdaq: MYOS), Joseph Mannello, issued the following letter to shareholders:...


Dec 06, 2017, 05:05 ET MYOS RENS Technology Enters Into Research Agreement With University Of California, Berkeley To Study Effects Of Fortetropin® On Skeletal Muscle Protein Synthetic Rate In Older Men And Women

MYOS RENS Technology Inc. ("MYOS" or "the Company") (Nasdaq: MYOS), has entered into a research agreement with the University of California,...